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ABSTRACT  
   
  Medical errors are now estimated to be the third leading cause of death in the 
United States (Makary & Daniel, 2016). Look-alike, sound- alike prescription drug mix-
ups contribute to this figure. The US Food and Drug Administration (FDA) and Institute 
for Safe Medication Practices (ISMP) have recommended the use of Tall Man lettering 
since 2008, in which dissimilar portions of confusable drug names pairs are capitalized in 
order to make them more distinguishable. Research on the efficacy of Tall Man lettering 
in differentiating confusable drug name pairs has been inconclusive and it is imperative 
to investigate potential efficacy further considering the clinical implications (Lambert, 
Schroeder & Galanter, 2015). The present study aimed to add to the body of research on 
Tall Man lettering while also investigating another possibility for the mechanism behind 
Tall Man’s efficacy, if it in fact exists. Studies indicate that the first letter in a word offers 
an advantage over other positions, resulting in more accurate and faster recognition 
(Adelman, Marquis & Sabatos-DeVito, 2010; Scaltritti & Balota, 2013). The present 
study used a 2x3 repeated measures design to analyze the effect of position on Tall Man 
lettering efficacy. Participants were shown a prime drug, followed by a brief mask, and 
then either the same drug name or its confusable pair and asked to identify whether they 
were the same or different. All participants completed both lowercase and Tall Man 
conditions. Overall performance measured by accuracy and reaction time revealed 
lowercase to be more effective than Tall Man. With regard to the position of Tall Man 
letters, a first position advantage was seen both in accuracy and reaction time. A first 
position advantage was seen in the lowercase condition as well, suggesting the location of 
the differing portion of the word matters more than the format used. These findings add 
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to the body of inconclusive research on the efficacy of Tall Man lettering in drug name 
confusion. Considering its impact on patient safety, more research should be conducted to 
definitively answer the question as to whether or not Tall Man should be used in practice. 
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CHAPTER 1 
INTRODUCTION 
Medical errors are on the rise. In fact, a staggering publication from researchers at 
Johns Hopkins University School of Medicine estimate medical errors to be the third 
leading cause of death in the United States (Makary & Daniel, 2016). Prescription drug 
errors have contributed to this figure, to include medication mix-ups of similar drug 
names. In 2001, the US Food and Drug Administration (FDA) Office of Generic Drugs 
launched the Name Differentiation Project, which asked manufacturers of 16 pairs of 
look-alike drug names to implement Tall Man lettering in an effort to minimize confusion 
(Food and Drug Administration, n.d.). Tall Man lettering capitalizes the dissimilar 
portions of confusable drug names in attempt to reduce medication errors. In 2008, the 
ISMP published “FDA and ISMP Lists of Look-Alike Drug Names with Recommended 
Tall Man Letters,” an unofficial list of confusable drug name pairs with a recommended 
bolded Tall Man lettering format (Institute for Safe Medication Practices, 2008). This list 
has been updated several times, most recently in June 2016 (Institute for Safe Medication 
Practices, 2016).  
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CHAPTER 2 
LITERATURE REVIEW 
Text Enhancements 
Text enhancements, such as Tall Man lettering, should exaggerate the differences 
between two words in order to identify a mismatch (Schell, 2009). One possible 
advantage of text enhancements such as Tall Man lettering is that it adds perceptual 
characteristics to provide additional information necessary when differentiating two 
similar words. Enhanced letters should be the most salient, and the first letters compared, 
when comparing drug names in a display sequence. However, real world time constraints 
may not allow pharmacists and other medical professionals to perceive each letter in a 
word equally or devote enough time to perceive each letter in the word to begin with.  
Additionally, enhancing the dissimilar portions of a word could result in lower perceptual 
processing of the rest of the word. This could be detrimental, as some confusable drug 
pairs have dissimilarities in more than one part of the word. For example, the confusable 
drug pair azaTHIOprine and aziTHROmycin have differences in all parts of the word, 
thus detracting attention from the unenhanced letters could be dangerous if they too 
possess cues that can assist the person trying to make the distinction. Even if a pair of 
drug names possess only one area of difference, enhancing these portions could create 
confusion with other drug names outside of the pair.  
Support for or against the use of Tall Man lettering in reducing drug name 
confusion may rest on which theory of word perception one subscribes to. If one uses 
bottom-up processing and perceives words as letter strings (letter-word perception), 
enhancing letters could be useful. However, if a top-down approach is utilized (word-
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letter perception), enhancing letters may not be helpful and could potentially result in 
worse performance. If words are perceived word as a whole, enhancing text can make the 
text appear more similar and be difficult to differentiate.  
Tall Man Lettering 
Tall Man lettering aims to attract attention to the dissimilar aspects of confusable 
drug names by capitalizing the differentiating letters. The ISMP list follows the CD3 rule 
whenever possible in order to encourage standardization. However, there are instances in 
which the CD3 rule does not make the words easier to distinguish and can actually make 
them more confusing (Institute for Safe Medication Practices, 2016). In fact, there are 
several variations of Tall Man to include: Mid Tall Man, CD3 Tall Man, and Wild Tall 
Man. Each variation has its own set of rules, as described in pages 24-25 of Darker, 
Gerret, Filik, Purdy & Gale (2011):  
“The Mid Tall Man rule: collect drug names into groups of two or more names 
that are orthographically similar (these groupings were determined in consultation with 
experts at the National Patient Safety Agency and the NHS Connecting for Health 
Initiative); on a letter-by-letter basis, start from either end of each drug name in a 
confusable group and work towards the middle; capitalise the first letters encountered at 
either end that differ across at least two drug names in the group, along with all letters 
occurring between them. Essentially, the entire critical portion of the drug name is 
capitalised, for example, cefixime, cefotaxime, ceftazidime and cefuroxime would 
become cefIXime, cefOTAXime, cefTAZIDime and cefUROXime.  
The CD3 Tall Man rule: collect drug names into groups and define the critical 
portions in the same way as for the Mid Tall Man rule, but capitalise a maximum of only 
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three letters per drug name. Where more than three letters are present in the critical 
portion of the drug name, capitalise the centre most three. Where this would result in 
letters that are common amongst all the drug names of the group in those positions being 
capitalised, then capitalise the next most peripheral letters that differ across at least two 
drug names. In order to prevent confusion with a lowercase letter ‘l’, the letter ‘i’ is not 
capitalized unless it is the initial letter of a proprietary drug name. Using the CD3 rule, 
cefixime, cefotaxime, ceftazidime and cefuroxime would become cefiXime and 
cefOTAxime, cefTAZidime and  cefUROxime.”  
The Wild Tall Man format does follow have any consistent rule, however is 
comprised of existing examples of Tall Man implementations (Appendix D). 
 
Mid Tall Man CD3 Tall Man Wild Tall Man 
azATHIOPRINE 
azITHROMYCIN 
cefOTAxime 
cefiXime 
azaTHIOprine 
aziTHROmycin 
Figure 1. Tall Man Lettering Variations  
 
Theoretical Support for Tall Man Lettering 
            Word Superiority Effect  
Reicher (1969) presented stimuli consisting of one or two individual letters, four-
letter words, and four-letter nonwords briefly in a tachistoscope, followed by a masking 
field with two individual letters serving as response alternatives. Participants were asked 
to choose which letter alternative matched what was shown previously. Overall, letters 
were identified more accurately when first shown a word rather than a single letter. When 
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asked, the majority of participants (8 of 9) stated they perceived words as word units and 
not as their individual letters. Wheeler (1970) replicated this study and also found that 
words were perceived more accurately by approximately 10%. These widely cited studies 
show the Word Superiority Effect, that words provide a context of meaning that enable 
individual letters to be more easily recognized. The Interactive Activation Model is a 
potential explanation for the Word Superiority Effect (McClelland & Rumelhart, 1981). 
This model is based on multiple levels of processing. In the context of word perception, 
this occurs at the visual feature level, letter level, and word level, with higher top-down 
processing also occurring at the word level. These levels are processed simultaneously in 
multiple letters.  Perception is driven by excitatory and inhibitory interactions at the 
visual feature, letter, and word levels. When viewing a word, detectors are activated for 
the features of those letters, letters, and words. A word is more easily perceived because 
more activations occur compared to letters and letter features.  
The Word Superiority Effect provides support for the Word Shape Model, which 
postulates that since words are perceived as units and not individual letters, the outline or 
shape of the word is what enables people to recognize words (Bouwhuis & Bouma, 
1979).  However, the Word Shape Model does not support several findings on Tall Man 
Lettering that yielded results no greater than performance with words presented in 
entirely in lowercase (Schell, 2009) and uppercase (Darker et al, 2011). Tall Man can 
result in a more similar word shape, especially in cases where large portions of the drug 
name are capitalized. If the Word Shape Model does not explain the use of Tall Man 
lettering, other models should be investigated to identified any possible mechanisms 
underlying Tall Man efficacy, if it exists.  
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 Models of Letter Processing 
Research has indicated that letters in words are perceived simultaneously rather 
than sequentially from left to right (Rumelhart & McClelland, 1982; Tydgat & Grainger, 
2009; Adelman, Marquis, & Sabatos-DeVito, 2010). Adelman et al. suggest that the 
identification of each letter begins at the same time, however attention or efficiency can 
decrease as letters progress from left to right. Such letter level phenomena are 
acknowledged within the simultaneous model of letter processing, and have been 
attributed to the attentional characteristics of letter detectors that result in different levels 
of signal strength throughout letter processing (Rumelhart & McClelland; Tydgat & 
Grainger). Adelman et al. investigated whether the left to right decrease in accuracy was 
due to attentional or efficiency degradation.  
 
First Position Advantage 
Research has found a significant first position advantage in letter processing 
within a word, in which the first letter of a word is recognized faster and more accurately 
compared to subsequent letters. Adelman, Marquis, and Sabatos-DeVito (2010) presented 
four-letter words briefly in eight brief durations ranging from 12-54 ms and asked 
participants to choose one of two alternatives, either the same word or a word with one 
letter changed. Accuracy improved when the display time increased, and critical display 
duration was identified in the 18-24 ms timeframe. At 18 ms participants performed at 
chance, however 6 added ms provided enough time for performance to surpass that of 
chance, regardless of the position in question. Essentially, no information was taken from 
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any of the four letters when the word was shown for 18ms, but some information was 
extracted from all four letters when show for 24ms.  This careful analysis revealed that 
initiation of letter identification occurred simultaneously, specifically when lower level 
information presents itself sometime between 18-24 ms. This finding negates the 
sequential model of letter processing that suggests words are read letter by letter from 
left-to-right, each letter taking 10-25 ms to process before moving on to the next. Words 
with changes to the first letter were identified more accurately compared to words with 
letter changes in the second, third, and fourth positions. Accuracy declined in positions 
from left to right.  
The first position advantage was replicated in a robust series of four experiments 
conducted by Scaltritti and Balota (2013), in which changes to the first letter in words, 
legal nonwords, and random consonant strings were recognized more accurately and 
quickly compared to letter changes in all other positions. The first position advantage 
persisted in words of varying lengths, and when word length was blocked and randomly 
mixed.  
 
Research on Tall Man showing Efficacy 
Tall Man lettering is one way to enhance text and draw attention to the 
dissimilarities between confusable drug names. Filik, Purdy, Gale, & Gerrett (2004) 
found Tall Man lettering to be effective in reducing drug name confusion when 
performing a visual search task. Non-healthcare professionals were shown a mock drug 
pack with a target drug name printed in either lowercase or Tall Man. The drug pack 
image had shading to make it appear three dimensional and contained drug information 
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such as dosage, form (e.g. capsules, tablets), the statement “Patient Pack 28” printed on 
the bottom left, and a vertical colored strip on the left side to simulate a packaging 
design. Confusable drug pairs had drug packs containing identical information except the 
drug name itself. A brief mask and fixation point were displayed following the target 
drug pack. Participants were then asked search for the target drug pack in an array of 20 
drug packs, which consisted of 19 low similarity drug name packs and one pack 
containing the confusable, highly similar drug name. Throughout the trials the confusable 
drug name pack would be shown in each of the 20 positions throughout the array. The 
target drug name was never displayed in any of the packs in the array during the 
experiment, only its corresponding, confusable drug name pair. In order to prevent 
participants from realizing the target drug name pack was never featured in the array, 20 
filler trails were shown containing matches. Half of the packs in the array featured drug 
names in Tall Man and half in lowercase. Each drug name had two stimulus files and was 
presented in both Tall Man and lowercase, however participants saw a drug name only 
once. Participants made significantly less errors when the Target drug names pack 
featured Tall Man lettering. When the target drug pack was in lowercase, participants 
would incorrectly identify the confusable drug name pack in the array as the target drug 
pack. This task corresponded to looking for a drug on a shelf, which has been identified 
as a point for drug errors in practice.  
Filik et al. (2010) found additional support for the use of Tall Man lettering in two 
experiments that featured both older adults and a larger sample size of healthcare 
professionals. In Experiment 1 both young and older adults were given a same/different 
judgment task, similar to Schell (2009) in which they were shown a drug name, followed 
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by a mask, and presented either the same drug name or its confusable pair. Participants 
were either shown the same drug name twice, or a confusable drug pair. This was 
repeated in both Tall Man and lowercase format, resulting in four conditions: 
lowercase/same, lowercase/different, Tall Man/same, Tall Man/different). Drug names in 
Tall Man resulted in significantly less errors (reporting that the two drugs were the same) 
compared to drug names in lowercase. In addition, it took participants longer to respond 
to different drug pairs in lowercase compared to Tall Man, indicating that Tall Man 
letters are perceived first and aids in discriminating between the two. Conversely, when 
two drug names were the same, participants took longer to respond to the Tall Man 
compared to lowercase. If the Tall Man letters are perceived first and they appear the 
same, the participant needed to scan the rest of the word to find whether or not other 
differences exist. It can be concluded that participants looked at entire word and did not 
rely on the Tall Man letters for making a determination. In Experiment 2, healthcare 
personnel were shown a drug name, followed by a mask, and asked whether or not it was 
present in a list of names. Tall Man formatting resulted in fewer errors and faster 
response times compared to those presented in lowercase.  
 
Research on Tall Man not showing efficacy 
Schell (2009) investigated the effect of text enhancement on the recognition of 
drug names in two studies using laypersons and pharmacy staff. Both experiments 
utilized a sequential task in which the prime stimulus drug name was shown, followed by 
a brief mask, and then shown the target stimulus drug name. Among laypeople, drug 
names presented in Tall Man format led to significantly more errors compared to drugs 
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presented in lowercase or color-based text enhancement. The errors included participants 
incorrectly identifying two drugs as different when they were the same, and incorrectly 
identifying two different drugs as being the same. When studied among pharmacy 
personnel, no significant differences in performance were seen between Tall Man 
lettering and other case enhancements or in Tall Man compared to those in lowercase.  
Filik, Purdy, Gale, & Gerrett (2006) conducted three experiments investigating 
the efficacy of both Tall Man lettering and color on confusable drug names. The first two 
experiments employed a same/different judgment task in which participants had to decide 
as quickly and accurately as possible whether or not two drug names presented side-by-
side on a computer screen where the same or different. Drug names pairs were presented 
in either lowercase or Tall Man format, and each format featured pairs that were the same 
and different. The task was measured by response time as it was seen as a measure of task 
difficulty. That is, if Tall Man lettering made the task easier to perform it should result in 
a faster response time.  In both experiments participants took longer to identify two 
words that were the same compared to when they were different, suggesting it is easier to 
detect differences in the words compared to scanning the entire words in order to 
determine two names as being the same. There were no differences in response times 
between lowercase and Tall Man formats when participants went into the experiment not 
knowing the goal of Tall Man lettering on drug name confusion (Experiment 1). 
However, when participants were told the goal of Tall Man lettering prior to the task it 
resulted in faster response times compared to the lowercase condition (Experiment 2). 
Prior to Experiment 3 participants were asked to subjectively rate different format 
enhancements including Tall Man, size (larger lowercase), color (red), italics, underlining 
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and boldface. Word pairs presented in lowercase without any manipulation were rated as 
most confusing. Word pairs with sections of red text were perceived as least confusing, 
so it was the enhancement chosen for Experiment 3. 
Experiment 3 employed a recognition memory task in which participants were 
asked to remember a list of drug names and then shown another list of drug names 
containing some of the same drug names mixed in with their confusable drug name 
(Filik, Purdy, Gale, & Gerrett, 2006). The task simulated the practical application in 
which a pharmacist looks for a specific drug name on a shelf among other similar drug 
names. Names containing Tall Man lettering were recognized more accurately than those 
presented in lowercase. The use of red letters did not have a significant effect on the 
recognition rate, and when combined with Tall Man lettering did not product better 
results than Tall Man lettering alone. Tall Man letters resulted in less false negative errors 
(false alarms), however did not significantly impact the prevalence of false positive errors 
(mistaking the confusable drug name for the target drug name). The results indicate that 
Tall Man letters may be useful in drawing attention to highly similar drug names, but 
does not necessarily make them less confusable when recalling from memory. These 
results did not support the use of Tall Man letter or colored enhancements in the practical 
application of reducing medication errors.  
 Darker et al. (2011) employed a forced-choice task in which a stimulus drug name 
was presented briefly, followed by presentation of both the stimulus drug name and 
confusable drug name. Drug names with Tall Man lettering performed no better than drug 
names presented in uppercase. Consequently, it may be possible that capital letters alone 
may help perceive differences between similar words, regardless of what letters they are. 
  12 
One possible explanation for this is that uppercase letters are more legible than lowercase 
letters (Tinker, 1963) due to their increased size (Sheedy et al., 2005). Uppercase letters 
may provide enough of a perceptual advantage on their own to drive the effect seen in 
drugs with Tall Man letters, rather than the contrast of the uppercase and lowercase 
letters. The argument for uppercase letters is supported in Darker et al.’s (2011) findings 
in which higher accuracy was achieved with Mid Tall Man compared CD3 Tall Man. 
Mid Tall Man capitalizes all letters that differ between two similar drug names, whereas 
CD3 Tall Man only capitalizes a maximum of three letters. The Mid Tall Man results in 
more capital letters in the majority of cases (75%).  It should be noted that there was no 
significant difference in accuracy between Mid Tall Man and uppercase, suggesting that 
capitalizing letters outside of the critical portion does help in the identification of a drug 
name.  
It is evident that research on the efficacy of Tall Man Lettering on drug name 
confusion is inconclusive. DeHenau, Becker, Bello, Liu, & Bix (2016) tested the efficacy 
of Tall Man lettering when several stimuli compete for one’s attention. Participants 
included both laypeople and healthcare providers. A change detection task was 
implemented by presenting a standard image, followed by a brief gray screen, and then a 
test image. Participants were asked to detect the change made to the standard image by 
pressing the space bar, and clicking the mouse on the location that was changed. The 
standard and test images were presented in a 4x4 grid of drug labels consisting of brand 
name, brand symbol, Rx status, route of administration and concentration. Only one drug 
name was changed to its confusable alternative in the array of 16 labels. Drug name pairs 
were either presented in Tall Man format or lowercase format. Results showed higher 
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change detection rates in confusable drug name pairs presented in Tall Man lettering 
compared to traditional format for both healthcare workers and laypeople. Change 
detection time was also faster for Tall Man format in both laypeople and healthcare 
workers. Laypersons were more likely than healthcare workers to detect a change. This 
difference between test groups may be explained by an age effect, as the layperson group 
was younger overall.  
Zhong et al. (2016) used pediatric pharmacy data from 42 children’s hospitals 
between 2004-2012 to test the effect of Tall Man lettering in practice. Using the 
published lists of LA-SA drugs from the ISMP, FDA, and Joint Commission, a list of 76 
look alike sound alike (LA-SA) drug name pairs was derived. The list was further 
reduced by selecting only those medications that were both pertinent to pediatric patients 
and easily confused when presented in practice, as identified by two pediatricians and one 
pharmacist. Ultimately, a list of 12 confusable drug pairs was selected for further 
analysis. Only generic names were analyzed in this study.  
 The drug errors were classified into eight patterns over a four-day period, in 
which a transition of one drug (Drug A) to its LA-SA drug (Drug B) took place with 
either no overlap or a one-day overlap of both medications being dispensed in the same 
day (Zhong et al., 2016). Two of the eight patterns included another transition back to the 
original drug (Drug A, Drug B, Drug A). The longitudinal effects of Tall Man lettering 
implementation were analyzed using segmented regression analysis. Of the 12 confusable 
pairs identified above, one pair did not show any potential errors (doxazosin-warfarin) 
and was not analyzed further. The rate for the 11 LA-SA drug pairs ranged from 0 to 2.9 
per 1000 hospitalizations. This yielded no statistically significant effects of Tall Man 
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implementation on drug error rates of the 11 LA-SA drugs when analyzed individually or 
as a group. Further, no significant changes were identified after 2007, despite this being 
the year Tall Man was widely implemented.  
 The research of Zong et al. (2016) is critical in our understanding of Tall Man 
lettering efficacy for several reasons. First, it was a longitudinal study that spanned eight 
years analyzing the effect of Tall Man lettering before and after its widespread 
implementation. Second, it used pharmacy specific data to detect potential error rates. 
Last, it was able to go beyond theoretical laboratory studies to investigate Tall Man in 
practice. However, there were several limitations to this study that should be noted. The 
data was limited to pediatric patients with a hospital stay of 4 days or longer. Second, 
only data captured in the Pediatric Healthcare Information System (PHIS) were used to 
derive the LA-SA word pair list. Another limiting factor was that brand names were 
changed to generic names due to PHIS only using generic names. This resulted in some 
word pairs not being less confusable (fluoxetine-tacrolimus).  Last, although Tall Man 
and other text enhancements were recommended widely in 2007, no formal 
implementation was required. Thus, it is difficult to know when and how such 
implementation occurred.   
 Lambert, Schroeder, & Galanter (2015) conducted a review Tall Man research 
and outlined the inconsistencies in results. One contention involves the methodologies 
used in the research. Another is whether result attribution actually belongs to the use of 
Tall Man lettering. In addition, most of the research has been conducted in the lab and 
even this research is conflicting. It is suggested that some of the supporting results are a 
result of demand characteristics, or participant knowledge of the task and expected 
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behavior. Table 1 (Lambert, Schroeder, & Galanter, 2015 p. 215) outlines inconsistencies 
in previous published experiments on the efficacy of Tall Man lettering. 
 
Table 1 
Summary of published experiments examining the efficacy of Tall Man lettering in drug 
name confusion. Reproduced from 1 (Lambert, Schroeder, & Galanter, 2015 p. 215).  
 
 
 
The Current Study 
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The present study aims to contribute to the empirical evidence for the efficacy of 
Tall Man lettering on drug name confusion. Since the results thus far have been 
inconclusive, we felt it was important to replicate some of the methods used to make this 
determination. The current study analyzes the effect of position on Tall Man lettering 
efficacy. It was predicted that drug names presented in Tall Man, regardless of position, 
would be discriminated more accurately and quickly than drug names presented in 
lowercase (H-1). It was also predicted that drug names whose differences occurred in the 
beginning of the word would be discriminated more accurately and more quickly than 
drug names with differences in the middle or end of the word (H-2).  
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CHAPTER 3 
METHOD 
Participants 
 A power analysis was generated with Gpower using an effect size F= 0.25, α
=.05, 1– β = 0.95 with two conditions, indicated a total of 30 participants be used in this 
design (Faul,	Erdfelder,	Lang,	&	Buchner,	2007). Participants were recruited online 
utilizing Arizona State University’s SONA system. The study required one session of 
approximately 45 minutes. Participants received course credit for participation in this 
study.  
 
Materials 
 The confusable drug name pairs were taken from the Food and Drug 
Administration (FDA) and the Institute for Safe Medication Practices’ (ISMP) FDA and 
ISMP Lists of Look-Alike Drug Names with Recommended Tall Man Letters (FDA & 
ISMP, 2011). Drug names were categorized based on the location of Tall Man lettering 
within the drug name. Three stimuli groups were formed based on whether Tall Man 
letters were located in the Beginning, Middle, or End of the drug name.  
In order to control for the location of the differing portions of each drug name 
pair, we ensured both drug names in a pair had the same number of lowercase letters, for 
example DAUNOrubicin and DOXOrubicin. The FDA and ISMP recommended CD3 
Tall Man format was followed as closely as possible when creating the three stimuli 
groups, however slight deviations were made in order to create equal numbers of stimuli 
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for each group. For example, the FDA and ISMP recommended Tall Man lettering for the 
pair hydrALAZINE and hydrOXYzine changed to hydrALAzine and hydrOXYzine. A 
full listing of the stimuli can be referenced in Appendix C. The confusable word pair 
Norman-Norbert used in the four practice trials came from Schell’s (2009) study. The 
experiment was collected using Inquisit software Version: 4.0.9.0 64bit (build 2657)  
(Inquisit 4, 2015). The study was implemented utilizing Inquisit Web Version: 5.0.7.0 
(Inquisit 5, 2016).  
 
Design 
This study utilized a 2x3 repeated measures design. There were two independent 
variables: letter format and position.  Letter format has two levels: lowercase and Tall 
Man: 
Lowercase: All letters are lowercase. For example, “bupropion.”  
Tall Man: Only the differentiating letters of the drug name are capitalized, as 
indicated by the FDA. For example, “buPROPion.” 
 
The second independent variable of position has three levels: Beginning, Middle, 
and End: 
Beginning: Differing portion is located in the beginning of the drug name. 
For example, “DOPamine.” 
 
Middle: Differing portion is located in the middle of the drug name. For 
example, “buPROPion.” 
 
End: Differing portion is located in the end of the drug name. For 
example, “predniSONE. 
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There are two dependent variables: reaction time and percentage of errors made in 
each condition. There were nine confusable drug name pairs for each position. Each 
confusable drug name pair had four trials to include two matches and two mismatches, as 
displayed in Table 2 below. 
 
Table 2 
 Four combinations were derived for each confusable drug name pair. 
Drug A  Drug B  
Drug B  Drug A  
Drug A  Drug A  
Drug B  Drug B  
 
Prime drug names were shown in Arial 14 point font. Target drug names 
following the 3 second mask were presented in Arial 14 point font in either lowercase or 
Tall Man lettering. For example, “bupropion” or “buPROPion.” Darker et al. (2011) 
found Arial 12 point font to be most commonly used in electronic prescribing software.  
 
Procedure   
Participants read the informed consent and clicked Continue to provide consent 
and proceed to the study. A brief demographic survey was completed, followed by an 
overview of the task and instructions (Appendix A). This study replicated the 
methodology from Schell (2009) as closely as possible. Participants were first shown an 
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asterisk (*) for 3 seconds to orient their eyes to the center of the screen. This was 
immediately followed by the prime drug name for 400ms, a row of x’s serving as the 
mask (XXXXXXXX) for 3 seconds, and finally the target name was presented (Figure 
1).  
 
Figure 1. Diagram illustrating the experimental sequence.  
 
Participants were asked to press E if the two drugs are different and I if they were 
the same. We asked the participants to go as fast as they could while making as few 
mistakes as possible since this was a reaction time task. Participants completed four 
practice trials (two matches and two mismatches) consisting of the confusable word pair 
Norman and Norbert (Schell, 2009). Screen shots of a practice trial sequence can be seen 
in Figures 2a-2e. 
TOLBUTamide
Fixation: 3 Sec
Mask: 3 Sec
Prime Drug: 400ms
XXXXXXXX
tolazamide
Target Drug
*
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Figure 2a. Instructions 
 
  
Figure 2b. Fixation (3 sec) 
 
 
 
Figure 2c. Prime Drug Name (400 ms) 
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Figure 2d.  Mask (3 sec) 
 
 
 
Figure 2e. Target Drug Name  
 
 Each condition had 108 trials and participants completed both and lowercase and 
Tall Man conditions, totaling 216 trials per participant excluding the four practice trials. 
The order of the conditions was counterbalanced to reduce any potential priming effect. 
The trials within each condition were also randomized. At the end of the study, 
participants were debriefed (Appendix B) and given credit for completion of the study.  
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CHAPTER 4 
RESULTS 
Accuracy 
Drug names presented in lowercase were discriminated more accurately (M=0.82, 
SD=0.09) than those presented in Tall Man (M=0.78, SD=0.11, F(1,29)= 6.4, p=.017). 
Additionally, an ANOVA revealed a significant effect of accuracy on position, F(2,58)= 
7.1, p=.002. Specifically, drug names with differences occurring in the beginning of the 
drug name were discriminated more accurately drug names with differences in other 
positions (see Figure 3). There was no interaction between Text Enhancement and 
Position.  
 
 
 
Figure 3. Line chart displaying mean accuracy percentages by position.  
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Reaction Time 
Mean reaction times are presented in Figure 4. Drug names in lowercase 
(M=1119.71, SD= 348.90) were discriminated faster than drug names in Tall Man, (M= 
1341.58, SD= 587.73; F(1, 29)= 7.4, p=0.011). Further, a one-way repeated measures 
ANOVA revealed a significant effect of position on reaction time, F(2, 58)= 7.9, 
p=0.001. Specifically, t-tests with Bonferroni correction revealed that drugs with 
differences in the beginning of the name (M=1162.23, SD=72.00) were discriminated 
faster than drugs with differences in the middle of the name (M=1289.65, SD= 90.40) 
and drug names with differences at the end (M=1244.09, SD=78.27.  
 
 
Figure 4. Line chart displaying mean reaction times by position. 
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CHAPTER 5 
DISCUSSION 
Overview of the Present Study 
This study aimed to add to the body of Tall Man literature to help determine 
whether or not it is effective in differentiating confusable drug names. In order to better 
understand the underlying mechanism of Tall Man lettering, we tested the use of Tall 
Man letters in the beginning, middle, or end of a drug name. The results indicated that 
drug names for which the differences are capitalized in the beginning are discriminated 
more accurately and more quickly compared to the other locations. However, this effect 
of location was also seen in the lowercase condition in which nothing is differentiated, 
leading us to conclude that the Tall Man lettering was not the reason behind the effect. In 
addition, words presented in lowercase were discriminated more accurately and more 
quickly than in the Tall Man format. These results are in line with the previous 
publications on the variety of outcomes seen when empirically testing Tall Man lettering 
(Lambert, Schroeder, & Galanter 2015).  
 
Strengths of the Present Study  
There were several strengths to the current research that should be noted. First, we 
aimed to replicate several elements of the methodology used in Schell (2009); the timing 
of our stimuli and mask sequence, practice trial stimuli, and lack of feedback throughout 
the task. Schell’s (2009) research is widely cited among literature on Tall Man lettering 
and found that Tall Man lettering resulted in the most amount of errors overall and the 
most false alarm errors when compared to no enhancements (lowercase) and color based 
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enhancements. Another strength of our study is that it is the first to test the position of 
Tall Man letters with a drug name to our knowledge. Considering the various results in 
the Tall Man literature, it was important to try and look at this methodology in a new 
way.  
 
Limitations of the Present Study 
 There were also several limitations to the current study that should be discussed. 
First, the FDA and ISMP Lists of Look-Alike Drug Names with Recommended Tall Man 
Letters (2011) recommends the use of bolded Tall Man letters. We were originally going 
to implement this, however the Inquisit software did not provide a simple way for doing 
this so it was omitted. Second, it was conducted in a laboratory that is quite different 
from healthcare environment in which Tall Man lettering is used. Participants had the 
benefit of a quiet, undisturbed environment and were free of distractions. Third, our 
sample consisted only of undergraduate college students that are younger than the 
average healthcare professional and lack the working knowledge of these drug names. 
Moving forward it would be beneficial to test this in a larger, more diverse sample to 
include pharmacy personnel and other healthcare professionals.  
 
Conclusions and Future Prospects 
Tall Man lettering should continue to be studied to understand if it really helps to 
distinguish confusable drug names and if so what is the mechanism for its efficacy. If the 
research continues to show null or very mixed results it might be worth taking a second 
look at the implementation of Tall Man lettering.   
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APPENDIX A  
STUDY INSTRUCTIONS 
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"In this study you will be asked to indicate if two drug names are different or the same.  
An asterisk (*) will appear, followed by the first drug name, a row of xxxxxxxx, and then 
the second drug will be presented.  
 
Put your middle or index fingers on the E and I keys. When pairs of drugs are presented, 
press E if the two drugs are different and I if they are the same. GO AS FAST AS YOU 
CAN while making as few mistakes as possible. 
 
Going too slow or making too many errors will result in an uninterpretable score." 
  32 
APPENDIX B  
DEBRIEF 
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Thank you for your participation in today’s study. We are interested in 
understanding the effect of text enhancements, such as Tall Man lettering, on 
differentiating similar prescription drug names. Previous research has been conducted 
with mixed results (Schell, 2008; Darker, Gerret, Filik, Purdy, & Gale, 2011; Zhong, 
Feinstein, Patel, Dai, & Feudtner, 2015). This study aims to expand on the current 
literature and contribute new findings that will ultimately aid in better differentiation of 
similar drug names. Medical errors, to include drug name errors, are now the third 
leading cause of death in the United States, killing 251,000 people each year (Makary & 
Daniel, 2016). Thus, it is important to understand why these errors continue and identify 
ways to successfully differentiate confusable drug names.  
All of the information collected in today’s study will be confidential, and there 
will be no way of identifying your individual responses in the data archive.  
We are not interested in any one individual’s responses; we are looking for general 
patterns that emerge with the aggregated data. Your participation today is appreciated and 
will help human factors engineers and designers to present prescription drug names in 
ways that are more easily distinguished from other similar names. We ask that you do not 
discuss the nature of the study with others who may later participate in it, as this could 
affect the validity of our research conclusions.  
If you have any questions concerning the research study, please contact the 
research team at: Ashley.Knobloch@asu.edu or Russel.Branaghan@asu.edu.  
If you have any questions about your rights as a subject/participant in this research, or if 
you feel you have been placed at risk, you can contact the Chair of the Human Subjects 
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Institutional Review Board, through the ASU Office of Research Integrity and 
Assurance, at (480) 965-6788. 
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APPENDIX C  
STIMULI LIST 
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Beginning 
DOPamine DOBUTamine 
DAUNOrubicin DOXOrubicin 
TOLBUTamide TOLAZamide 
CISplatin CARBOplatin 
IDArubicin DOXOrubicin* 
FLUoxetine DULoxetine 
DULoxetine PARoxetine 
FLUoxetine PARoxetine 
PHENobarbital PENTobarbital 
 
Middle  
vinCRIStine vinBLAStine 
cloZAPine cloNIDine 
rifAXIMin rifAMPin 
hydrALAzine 
(hydrALAZINE)* hydrOXYzine* 
methylTESTOSTERone methylPREDNISOLone (methylPREDNISolone) 
niCARDipine (niCARdipine)* niMODipine 
azaTHIOPRine 
(azaTHIOprine) azaCITIDine 
lamOTRIGine (lamoTRIgine) lamIVUDine (lamiVUDine) 
sulfaSALAzine sulfadDIAzine (sulfADIAZINE)* 
 
End 
chlorproPAMIDE chlorproMAZINE* 
clomiPRAMINE clomiPHENE 
cycloSERINE cycloSPORINE 
metRONIDAZOLE (metroNIDAZOLE) metFORMIN 
metyrOSINE (metyroSINE) metyrAPONE (metyraPONE) 
mitoXANTRONE* mitoMYCIN (mitoMYcin) 
oxyMORPHONE (oxyMORphone) oxyCODONE 
romiPLOSTIM (romiPLOStim) romiDEPSIN (romiDEPsin) 
quiNINE quiNIDINE (quiNIDine) 
 
 
(Original Tall Man lettering recommendation) 
Table 1. FDA–Approved List of Generic Drug Names with Tall Man Letters 
Table 2. ISMP List of Additional Drug Names with Tall Man Letters*** 
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(Original Tall Man lettering recommendation) 
Drug names in Bold with asterisk* denotes they are in Both Tables 
 
 
Stimuli List  
All Stimuli were taken from the FDA and ISMP Lists of Look-Alike Drug Names with 
Recommended Tall Man Letters (2016). This list can be accessed at: 
https://www.ismp.org/Tools/tallmanletters.pdf 
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APPENDIX D  
WILD TALL MAN FORMAT 
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azaTHIOprine  aziTHROmycin 
carBAMAZepine carBIMazole 
cefACLOR  cefADROXIL 
cefALEXIN  cefTRIAZONE 
cefIXime  cefOTAXime 
cefTAZIDime  cefUROXime  
clomiFENE  clomiPRAMINE 
Depo-MEDRONE Depo-PROVERA 
diPYRIDAMOLE diSOPYRAMIDE 
DOPamine  DOBUTamine 
foliC acid  foliNIC acid 
gliCLAzide  glipiZIDE 
mercaptAMINE mercaptOPURINE 
NICARdipine N IFEdipine 
peniciLLAMINE peniciLLIN  
PregABALIN  PregADAY 
RifADIN  RifINAH 
vinBLAStine  vinCRIStine 
ZoFRAN  ZoTON 
zoLPIDEM  zoPICLONE 
 
 
 
List reproduced from (Darker, Gerret, Filik, Purdy & Gale, 2011) 
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